source
- Roche commits $750 million to double Oregon plant capacity as obesity drug push growsRoche's Genentech announced a $750 million investment to enlarge its device fill-finish facility in Hillsboro, Oregon. The expansion will double the plant's size and add end-to-end capabilities fo…
- Scribe Therapeutics’ early-stage IPO surges 43% as epigenetic cholesterol drug enters clinicScribe Therapeutics filed for an IPO while its lead epigenetic therapy moves into early clinical testing, a rare combination in a market that prefers later-stage, de-risked offerings. The company…